Cargando…

(18)F–FDG-PET/CT and diffusion-weighted MRI for monitoring a BRAF and CDK 4/6 inhibitor combination therapy in a murine model of human melanoma

BACKGROUND: The purpose of the study was to investigate a novel BRAF and CDK 4/6 inhibitor combination therapy in a murine model of BRAF-V600-mutant human melanoma monitored by (18)F–FDG-PET/CT and diffusion-weighted MRI (DW-MRI). METHODS: Human BRAF-V600-mutant melanoma (A375) xenograft-bearing bal...

Descripción completa

Detalles Bibliográficos
Autores principales:	Eschbach, Ralf S., Kazmierczak, Philipp M., Heimer, Maurice M., Todica, Andrei, Hirner-Eppeneder, Heidrun, Schneider, Moritz J., Keinrath, Georg, Solyanik, Olga, Olivier, Jessica, Kunz, Wolfgang G., Reiser, Maximilian F., Bartenstein, Peter, Ricke, Jens, Cyran, Clemens C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5774089/ https://www.ncbi.nlm.nih.gov/pubmed/29347968 http://dx.doi.org/10.1186/s40644-018-0135-y

Ejemplares similares

Integrin-targeted quantitative optoacoustic imaging with MRI correlation for monitoring a BRAF/MEK inhibitor combination therapy in a murine model of human melanoma
por: Kazmierczak, Philipp M., et al.
Publicado: (2018)

(68)Ga-TRAP-(RGD)(3) Hybrid Imaging for the In Vivo Monitoring of α(v)ß(3)-Integrin Expression as Biomarker of Anti-Angiogenic Therapy Effects in Experimental Breast Cancer
por: Kazmierczak, Philipp M., et al.
Publicado: (2016)

Contrast-Enhanced Ultrasound with VEGFR2-Targeted Microbubbles for Monitoring Regorafenib Therapy Effects in Experimental Colorectal Adenocarcinomas in Rats with DCE-MRI and Immunohistochemical Validation
por: Eschbach, Ralf Stefan, et al.
Publicado: (2017)

Monitoring Cell Death in Regorafenib-Treated Experimental Colon Carcinomas Using Annexin-Based Optical Fluorescence Imaging Validated by Perfusion MRI
por: Kazmierczak, Philipp M., et al.
Publicado: (2015)

Correlation of Perfusion MRI and (18)F-FDG PET Imaging Biomarkers for Monitoring Regorafenib Therapy in Experimental Colon Carcinomas with Immunohistochemical Validation
por: Eschbach, Ralf S., et al.
Publicado: (2015)

Semi-Automatic MRI Feature Assessment in Small- and Medium-Volume Benign Prostatic Hyperplasia after Prostatic Artery Embolization
por: Schmidt, Vanessa F., et al.
Publicado: (2022)

Monitoring Early Response to Anti-Angiogenic Therapy: Diffusion-Weighted Magnetic Resonance Imaging and Volume Measurements in Colon Carcinoma Xenografts
por: Schneider, Moritz Jörg, et al.
Publicado: (2014)

Regorafenib Effects on Human Colon Carcinoma Xenografts Monitored by Dynamic Contrast-Enhanced Computed Tomography with Immunohistochemical Validation
por: Cyran, Clemens C., et al.
Publicado: (2013)

Identification and characterization of myocardial metastases in neuroendocrine tumor patients using 68Ga-DOTATATE PET-CT
por: Kunz, Wolfgang G., et al.
Publicado: (2018)

The added diagnostic value of complementary gadoxetic acid-enhanced MRI to (18)F-DOPA-PET/CT for liver staging in medullary thyroid carcinoma
por: Puhr-Westerheide, Daniel, et al.
Publicado: (2019)

Circulating miR-21 as a prognostic biomarker in HCC treated by CT-guided high-dose rate brachytherapy
por: Stechele, Matthias, et al.
Publicado: (2023)

Diagnostic performance of PET/CT in the detection of liver metastases in well-differentiated NETs
por: Grawe, Freba, et al.
Publicado: (2023)

The assessment of left ventricular mechanical dyssynchrony from gated (99m)Tc-tetrofosmin SPECT and gated (18)F-FDG PET by QGS: a comparative study
por: Lehner, Sebastian, et al.
Publicado: (2021)

Post-therapeutic microRNA-146a in liquid biopsies may determine prognosis in metastatic gastrointestinal cancer patients receiving (90)Y-radioembolization
por: Hirner-Eppeneder, Heidrun, et al.
Publicado: (2023)

Cost-effectiveness of short-protocol emergency brain MRI after negative non-contrast CT for minor stroke detection
por: Puhr-Westerheide, Daniel, et al.
Publicado: (2021)

Validation of the SSTR-RADS 1.0 for the structured interpretation of SSTR-PET/CT and treatment planning in neuroendocrine tumor (NET) patients
por: Grawe, Freba, et al.
Publicado: (2023)

The assessment of left ventricular volume and function in gated small animal (18)F-FDG PET/CT imaging: a comparative study of three commercially available software tools
por: Zacherl, Mathias J., et al.
Publicado: (2023)

Comparison of transient and permanent LAD ligation in mice using 18F-FDG PET imaging
por: Fischer, Maximilian, et al.
Publicado: (2022)

Comparison of metabolic and functional parameters using cardiac 18F-FDG-PET in early to mid-adulthood male and female mice
por: Fischer, Maximilian, et al.
Publicado: (2021)

(18)F-PSMA-1007 PET/CT for response assessment in patients with metastatic renal cell carcinoma undergoing tyrosine kinase or checkpoint inhibitor therapy: preliminary results
por: Mittlmeier, L. M., et al.
Publicado: (2020)

Cardiac 18F-FDG Positron Emission Tomography: An Accurate Tool to Monitor In vivo Metabolic and Functional Alterations in Murine Myocardial Infarction
por: Fischer, Maximilian, et al.
Publicado: (2021)

(18)F-FDG PET/CT for Response Assessment in Pediatric Sebaceous Carcinoma of the Parotid Gland
por: Holzgreve, Adrien, et al.
Publicado: (2020)

Assessment of right ventricular sympathetic dysfunction in patients with arrhythmogenic right ventricular cardiomyopathy: An (123)I-metaiodobenzylguanidine SPECT/CT study
por: Todica, Andrei, et al.
Publicado: (2018)

(18)F-FDG-PET/CT in Patients with Advanced, Radioiodine Refractory Thyroid Cancer Treated with Lenvatinib
por: Ahmaddy, Freba, et al.
Publicado: (2021)

Preoperative Imaging with [(18)F]-Fluorocholine PET/CT in Primary Hyperparathyroidism
por: Dekorsy, Franziska J., et al.
Publicado: (2022)

[(18)F]FDG PET accurately differentiates infected and non-infected non-unions after fracture fixation
por: Wenter, Vera, et al.
Publicado: (2016)

Total Tumor Volume on (18)F-PSMA-1007 PET as Additional Imaging Biomarker in mCRPC Patients Undergoing PSMA-Targeted Alpha Therapy with (225)Ac-PSMA-I&T
por: Unterrainer, Lena M., et al.
Publicado: (2022)

A Multi-Scale and Multi-Technique Approach for the Characterization of the Effects of Spatially Fractionated X-ray Radiation Therapies in a Preclinical Model
por: Romano, Mariele, et al.
Publicado: (2021)

Incidental Finding of a PSMA-Positive Pancreatic Cancer in a Patient Suffering from a Metastasized PSMA-Positive Prostate Cancer
por: Sirtl, Simon, et al.
Publicado: (2021)

Correlation of an Index-Lesion-Based SPECT Dosimetry Method with Mean Tumor Dose and Clinical Outcome after (177)Lu-PSMA-617 Radioligand Therapy
por: Völter, Friederike, et al.
Publicado: (2021)

MEK + CDK4 a regimen for non-BRAF V6000 melanoma
por: Sosman, Jeff
Publicado: (2015)

CDK12 is hyperactivated and a synthetic-lethal target in BRAF-mutated melanoma
por: Houles, Thibault, et al.
Publicado: (2022)

CDK4 phosphorylation status and rational use for combining CDK4/6 and BRAF/MEK inhibition in advanced thyroid carcinomas
por: Pita, Jaime M., et al.
Publicado: (2023)

Feasibility of Different Tumor Delineation Approaches for (18)F-PSMA-1007 PET/CT Imaging in Prostate Cancer Patients
por: Mittlmeier, Lena M., et al.
Publicado: (2021)

Expansive arterial remodeling of the carotid arteries and its effect on atherosclerotic plaque composition and vulnerability: an in-vivo black-blood 3T CMR study in symptomatic stroke patients
por: Saam, Tobias, et al.
Publicado: (2016)

Quantitative myocardial perfusion SPECT/CT for the assessment of myocardial tracer uptake in patients with three-vessel coronary artery disease: Initial experiences and results
por: Lehner, Sebastian, et al.
Publicado: (2021)

Follow-Up 18F-FDG PET/CT versus Contrast-Enhanced CT after Ablation of Liver Metastases of Colorectal Carcinoma—A Cost-Effectiveness Analysis
por: Schnitzer, Moritz L., et al.
Publicado: (2020)

Targeting CDK2 overcomes melanoma resistance against BRAF and Hsp90 inhibitors
por: Azimi, Alireza, et al.
Publicado: (2018)

(68)Ga-EMP-100 PET/CT—a novel ligand for visualizing c-MET expression in metastatic renal cell carcinoma—first in-human biodistribution and imaging results
por: Mittlmeier, Lena M., et al.
Publicado: (2021)

Metabolic patterns on [(18)F]FDG PET/CT in patients with unresectable stage III NSCLC undergoing chemoradiotherapy ± durvalumab maintenance treatment
por: Holzgreve, Adrien, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_1t3paejahp4ho258sjh1bep42l